Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter, 3-Period Incomplete Block, Multidose Crossover Study to Determine the Effect on Lung Function of Indacaterol (150 and 300 micrograms o.d.) in Patients With Moderate to Severe COPD [chronic obstructive pulmonary disease], Using Tiotropium [tiotropium bromide] (18 micrograms o.d.) as an Active Control

Next Previous
Search
Trial Profile

A Phase III, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter, 3-Period Incomplete Block, Multidose Crossover Study to Determine the Effect on Lung Function of Indacaterol (150 and 300 micrograms o.d.) in Patients With Moderate to Severe COPD [chronic obstructive pulmonary disease], Using Tiotropium [tiotropium bromide] (18 micrograms o.d.) as an Active Control

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Indacaterol (Primary) ; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Novartis

Most Recent Events

  • 05 Nov 2009 Results presented at the 75th Annual Meeting of the American College of Chest Physicians: Chest 2009.
  • 30 Jan 2009 Actual patient numbers (169) added as reported by ClinicalTrials.gov.
  • 30 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top